| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -10.7 | -10.8 |
| EPS (diluted, $ a share) | $-0.22 | $-0.22 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: FLNA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Filana Therapeutics, Inc.: key numbers
- Share price
- $0.4809Close, Nov 17
- Market cap
- $24.2M
- Shares outstanding
- 50.27MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Filana Therapeutics, Inc.
All →Filana Therapeutics Leadership Change
Filana Therapeutics appointed Jill M. Quigley to its Board of Directors as a Class I director, effective November 8, 2026. Ms. Quigley brings over 20 years of biopharma leadership experience, including previous CEO and COO roles at Genuiti Therapeutics and Passage Bio. Her appointment is intended to support the company as it prepares for a Phase 2a clinical study of simufilam in TSC-related epilepsy.
Filana Therapeutics Financial Results
Filana Therapeutics reported Q3 2026 financial results, including a net loss of $10.7 million and a cash balance of $47.0 million. The company announced that patient screening for its Phase 2a study of simufilam in TSC-related epilepsy is expected to begin by Q1 2027 following the recent lifting of an FDA clinical hold.
“Simufilam has the potential to make a meaningful difference for patients with TSC-related epilepsy. We began working toward activating clinical study sites as soon as FDA lifted the clinical hold in September. Patient screening is expected to begin by the first quarter of 2027.”
Rick Barry, President and Chief Executive Officer
Filana Therapeutics Court & Legal Update
The U.S. Court of Appeals for the Fifth Circuit vacated a lower court's order that had granted class certification in a securities class action against Filana Therapeutics. The appellate court ruled that the district court misapplied legal standards regarding market efficiency and 'meme-stock' dynamics, remanding the case for further proceedings.
- Counterparty
- U.S. District Court for the Western District of Texas
Filana Therapeutics President & CEO Richard Barry Buys $278K of Stock
Richard Barry, President & CEO, bought 306,813 shares of Filana Therapeutics, Inc. at $0.9 to $0.92 a share (average $0.9065) in 2 transactions, worth $278K in total between Sep 29, 2026 and Sep 30, 2026. Shares held after the trade: 1,337,964 (+8.1%).
- Value
- $278K
- Shares
- 306,813
- Average price
- $0.9065
- Role
- President & CEO
- Holding change
- +8.1%
- Trade date
- Sep 29, 2026 to Sep 30, 2026
Filana Therapeutics President & CEO Richard Barry Buys $78.2K of Stock
Richard Barry, President & CEO, bought 93,091 shares of Filana Therapeutics, Inc. at $0.84 a share, worth $78.2K in total on Sep 28, 2026. Shares held after the trade: 1,031,151 (+9.9%).
- Value
- $78.2K
- Shares
- 93,091
- Price
- $0.8400
- Role
- President & CEO
- Holding change
- +9.9%
- Trade date
- Sep 28, 2026
Filana Therapeutics Business Update
The FDA has lifted a full clinical hold on Filana Therapeutics' IND application for simufilam, allowing the company to proceed with a Phase 2a proof-of-concept study in TSC-related epilepsy. The company expects to begin patient screening by Q1 2027 and has already completed trial-readiness activities including site identification and drug supply preparation.
- Counterparty
- FDA